JoannaMeehanRhodesMDMSCE

PubMed

• Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.
  Nilanjan Ghosh, Toby A Eyre, Jennifer R Brown, Nicole Lamanna, Beenish S Manzoor
  American Journal of Hematology. 2024-12-19
• 1 citations
  Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from t...
  William G Wierda, Nirav N Shah, Chan Y Cheah, David Lewis, Marc S Hoffmann
  The Lancet. Haematology. 2024-09-01
• The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas.
  Rahul S Bhansali, Fredrik Ellin, Thomas Relander, Miao Cao, Wenrui Li
  Blood Advances. 2024-07-09

Abstracts/Posters

• Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement
  Joanna M Rhodes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
  Joanna Rhodes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

• Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA) 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019